Jun 20 |
XOMA Declares Quarterly Preferred Stock Dividends
|
May 14 |
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
|
May 10 |
XOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss
|
May 9 |
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
|
May 7 |
Certara, Inc. (CERT) Q1 Earnings Meet Estimates
|
May 7 |
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
|
Apr 25 |
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
|
Apr 24 |
Actym Therapeutics Appoints Thomas Smart as CEO
|
Apr 3 |
XOMA Corporation Announces Closing of Tender Offer
|